Abstract：
Antibody-drug conjugates (ADCs) are a class of targeted biological agents that link cytotoxic drugs to monoclonal antibodies through linkers. The monoclonal antibody targets tumor cells and transports small-molecule cytotoxic drugs for specific delivery and minimal off-target side effects. September 30, 2022, 14 anti-tumor ADC drugs have been approved for marketing in the world, and four ADCs have been approved in China. With the improvement of the clinical accessibility of ADC drugs, clinicians urgently need to understand the molecular characteristics and mechanisms of ADCs, and clarify the indications for rational use of drugs. Patients\' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. In view of this, on the basis of the \"Expert Consensus on the Clinical Application of Antibody-drug Conjugates for the Treatment of Malignant Tumors (2020 edition)\" , Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti-Cancer Association fully combines the existing clinical research evidence and the feasibility of current ADC drugs in China to update the consensus content. This consensus aims to provide a systematic overview of ADC drugs, so as to provide practical and effective suggestions and references for clinicians to apply and manage ADC drugs more accurately.
抗体药物偶联物(ADC)是一类通过连接子将细胞毒性药物连接到单克隆抗体的靶向生物制剂，可高效靶向转运至目标肿瘤细胞而发挥抗肿瘤作用。截至2022年9月30日，全球已经有14种抗肿瘤ADC药物获得批准上市，中国获得批准上市的ADC有4种。随着ADC药物临床可及性的提高，临床医师亟需深入熟悉其分子特征和机制，明确适应证以合理用药。此外，选择合适的剂量和疗程，有效管理不良反应，可指导临床用药，甚至改善患者的预后转归。鉴于此，中国抗癌协会肿瘤药物临床研究专业委员会在《抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)》的基础上，基于临床研究证据，结合中国目前ADC药物的可及性，对共识进行更新，旨在对ADC药物进行系统性概述，从而为临床医师更精准地应用和管理ADC药物提供切实有效的建议和参考。.
抗体药物偶联物(ADC)是一类通过连接子将细胞毒性药物连接到单克隆抗体的靶向生物制剂，可高效靶向转运至目标肿瘤细胞而发挥抗肿瘤作用。截至2022年9月30日，全球已经有14种抗肿瘤ADC药物获得批准上市，中国获得批准上市的ADC有4种。随着ADC药物临床可及性的提高，临床医师亟需深入熟悉其分子特征和机制，明确适应证以合理用药。此外，选择合适的剂量和疗程，有效管理不良反应，可指导临床用药，甚至改善患者的预后转归。鉴于此，中国抗癌协会肿瘤药物临床研究专业委员会在《抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)》的基础上，基于临床研究证据，结合中国目前ADC药物的可及性，对共识进行更新，旨在对ADC药物进行系统性概述，从而为临床医师更精准地应用和管理ADC药物提供切实有效的建议和参考。.
摘要：
暂无翻译
